- Trials with a EudraCT protocol (61)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
61 result(s) found for: Abdominal x-ray.
Displaying page 1 of 4.
EudraCT Number: 2009-010968-42 | Sponsor Protocol Number: DGD-44-045 | Start Date*: 2009-07-07 | ||||||||||||||||
Sponsor Name:GUERBET | ||||||||||||||||||
Full Title: Efficacy evaluation of DOTAREM®-enhanced MRA compared to GADOVIST®–enhanced MRA in the diagnosis of clinically significant abdominal or lower limb arterial diseases | ||||||||||||||||||
Medical condition: Patient suffering from abdominal or lower limb arterial diseases | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: FR (Completed) DE (Completed) ES (Completed) AT (Completed) IT (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2015-004430-96 | Sponsor Protocol Number: 201600107 | Start Date*: 2017-12-11 |
Sponsor Name:University Medical Center Groningen | ||
Full Title: Short-term Testosterone replacement in testicular cancer survivors to treat overweight and improve cardiometabolic risk | ||
Medical condition: Testicular cancer | ||
Disease: | ||
Population Age: Adults | Gender: Male | |
Trial protocol: NL (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2004-000711-26 | Sponsor Protocol Number: IOM-114 | Start Date*: 2004-12-22 |
Sponsor Name:Bracco Imaging S.p.A. | ||
Full Title: ABDOMINAL COMPUTED TOMOGRAPHY: IOMERON®400 VS VISIPAQUE™320 ENHANCEMENT (ACTIVE). | ||
Medical condition: subjects with mild to moderate renal impairment scheduled to undergo clinically-indicated IV contrast –enhanced MDCT scanning of the liver | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Completed) SE (Prematurely Ended) GB (Prematurely Ended) IT (Completed) | ||
Trial results: View results |
EudraCT Number: 2004-000712-42 | Sponsor Protocol Number: IOM-115 | Start Date*: 2004-12-22 |
Sponsor Name:Bracco Imaging S.p.A. | ||
Full Title: Enhacement of the lower extremities computed tomography: IOMERON®-400 VS VISIPAQUE™-320 (ELECTIV). | ||
Medical condition: subjects with mild to moderate renal impairment (SCr =1.5-2.5 mg/dL and/or calculated CrCl = 10-60 mL/min) who undergo clinically-indicated IV contrast-enhanced MDCTA scanning of the lower extremit... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Completed) SE (Completed) GB (Prematurely Ended) IT (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2005-002995-13 | Sponsor Protocol Number: S28720 UZ KUL | Start Date*: 2006-01-23 |
Sponsor Name:UZLeuven | ||
Full Title: An open label Phase II trial to investigate the cardiac effects of pegylated liposomal doxorubicine (Caelyx) in elderly breast cancer patients with new imaging and biochemical techniques. | ||
Medical condition: histologically proven early breast cancer requiring adjuvant chemotherapy according to the treating physician (lymph node positive or other features of high risk according to St-Gallen criteria). 1... | ||
Disease: | ||
Population Age: Elderly | Gender: Female | |
Trial protocol: BE (Completed) | ||
Trial results: View results |
EudraCT Number: 2005-000535-18 | Sponsor Protocol Number: ML17632 | Start Date*: 2005-05-18 |
Sponsor Name:Roche Pharma (Schweiz) AG | ||
Full Title: Prospective, multicenter study to evaluate the renal safety of 6 mg ibandronic acid infusions over 15 min or 60 min in patients with metastatic bone disease due to breast cancer. | ||
Medical condition: The target population for this trial are female patients with primary breast cancer with metastatic bone disease. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2018-000754-22 | Sponsor Protocol Number: IBP-9414-020 | Start Date*: 2019-10-14 | |||||||||||
Sponsor Name:Infant Bacterial Therapeutics AB (IBT) | |||||||||||||
Full Title: A randomized, double blind, parallel-group, placebo controlled study to evaluate the efficacy and safety of IBP-9414 in premature infants 500-1500g birth weight in the prevention of necrotizing ent... | |||||||||||||
Medical condition: Necrotizing Enterocolitis (NEC) | |||||||||||||
|
|||||||||||||
Population Age: Preterm newborn infants, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) FR (Completed) HU (Completed) ES (Ongoing) BG (Completed) PL (Completed) RO (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-002568-27 | Sponsor Protocol Number: PM-C-0172 | Start Date*: 2006-05-08 | |||||||||||
Sponsor Name:Sanofi-Synthelabo Groupe | |||||||||||||
Full Title: A randomized, double blind, two-arm placebo controlled, 12-Month study of the effects of rimonabant 20mg once daily on the amount and the activity of visceral fat in abdominally obese patients with... | |||||||||||||
Medical condition: Abdominally obese patients with metabolic syndrome | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) ES (Completed) DK (Completed) SE (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-023538-22 | Sponsor Protocol Number: LY107 | Start Date*: 2011-08-30 |
Sponsor Name:Lipid Pharmaceuticals | ||
Full Title: Lýsi sem hægðalyf fyrir börn | ||
Medical condition: The primary objective of this trial is to investigate the laxative effect of Lysisstílar (Free Fatty Acids suppositories) as compared to Klyx. Participants are children aged 1 year old to 17 year... | ||
Disease: | ||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: IS (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2007-003244-30 | Sponsor Protocol Number: no sponsor | Start Date*: 2007-11-15 | |||||||||||
Sponsor Name:Rijnstate Hospital | |||||||||||||
Full Title: Diazoxide-Mediated Insulin Suppression in Hyperinsulinemic Obese Men, part III. | |||||||||||||
Medical condition: Hyperinsulinemic men with BMI 30-35 kg/m2 | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male | ||||||||||||
Trial protocol: NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-005644-92 | Sponsor Protocol Number: MDA-STS-06 | Start Date*: 2007-04-04 |
Sponsor Name:Antonio Cubillo Gracián (Servicio de Oncología Médica - Hospital MD Anderson) | ||
Full Title: ENSAYO CLÍNICO ABIERTO, NO ALEATORIZADO, PILOTO, EN FASE II, DE LA COMBINACIÓN DE IFOSFAMIDA Y DOXORRUBICINA LIPOSÓMICA SEGUIDO DE RADIOTERAPIA COMO TRATAMIENTO ANTINEOPLÁSICO NEOADYUVANTE EN PACI... | ||
Medical condition: PACIENTES CON SARCOMA DE PARTES BLANDAS DE EXTREMIDADES DE ALTO GRADO (PATIENTS WITH OF SOFT PARTS SARCOMA OF HIGH DEGREE EXTREMITIES) | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2005-001876-11 | Sponsor Protocol Number: UZL/MBC0501 | Start Date*: 2005-08-04 |
Sponsor Name:UZLeuven | ||
Full Title: A randomized phase II trial exploring feasibility of densification and optimal sequencing of postoperative adjuvant Fluorouracil, Epirubicin plus Cyclophosphamide (FEC) and Docetaxel chemotherapy i... | ||
Medical condition: The rationale of this randomized phase II study is to investigate the feasibility of sequenced densified FEC and docetaxel based regimens in patients with primary operable high-risk breast cancer. ... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: BE (Completed) | ||
Trial results: View results |
EudraCT Number: 2008-003997-17 | Sponsor Protocol Number: GBG43 | Start Date*: 2009-05-25 |
Sponsor Name:GBG Forschungs GmbH | ||
Full Title: A randomized phase III study to determine the efficacy of a taxane and bevacizumab with or without capecitabine as first line chemotherapy in patients with metastatic breast cancer | ||
Medical condition: First line chemotherapy at patients with metastatic breast cancer | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2005-001546-17 | Sponsor Protocol Number: GBG40 | Start Date*: Information not available in EudraCT |
Sponsor Name:German Breast Group | ||
Full Title: GeparQuattro: A randomized phase III study exploring the efficacy of Capecitabine given concomitantly or in sequence to EC - Doc with or without Trastuzumab as neoadjuvant treatment of primary brea... | ||
Medical condition: Primary breast cancer | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2006-000320-14 | Sponsor Protocol Number: D6997L00002 (9238SW0001) | Start Date*: 2006-03-29 |
Sponsor Name:AstraZeneca oy | ||
Full Title: Anastrozole monotherapy versus maximal oestrogen blockage with anastrozole and fulvestrant comination therapy: An open, randomised, comparative, phase III multicentre study in postmenopausal women ... | ||
Medical condition: Hormone receptor positive breast cancer in first relapse after primary treatment of localised tumour, in postmenopausal women. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Female | |
Trial protocol: FI (Completed) PT (Completed) IS (Completed) FR (Completed) IT (Completed) | ||
Trial results: View results |
EudraCT Number: 2011-004714-41 | Sponsor Protocol Number: GBG69 | Start Date*: 2012-05-18 | |||||||||||
Sponsor Name:GBG Forschungs GmbH | |||||||||||||
Full Title: A randomized phase III trial comparing nanoparticle-based paclitaxel with solvent-based paclitaxel as part of neoadjuvant chemotherapy for patients with early breast cancer (GeparSepto) | |||||||||||||
Medical condition: Patients with primary breast cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-002727-16 | Sponsor Protocol Number: IP-CAT-GC-03 | Start Date*: 2007-03-06 | |||||||||||
Sponsor Name:Fresenius Biotech GmbH | |||||||||||||
Full Title: Multicenter, open-label phase II study to evaluate the safety and efficacy of the tri-functional bispecific antibody catumaxomab (anti-EpCAM x anti-CD3) in patients with gastric adenocarcinoma afte... | |||||||||||||
Medical condition: Gastric Neoplasm malignant | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) AT (Completed) GB (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-004636-52 | Sponsor Protocol Number: 2005AN005 | Start Date*: 2006-02-20 |
Sponsor Name:Heart of England NHS Foundation Trust | ||
Full Title: Randomised Double-Blind Placebo Controlled Trial of 40mg/day of Atorvastatin on Reduction in Severity of Sepsis in Ward Patients | ||
Medical condition: Sepsis is the clinical syndrome defined by the presence of both infection and a systemic inflammatory response. Sepsis is common in general medical and surgical wards with an estimated prevalence ... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (GB - no longer in EU/EEA) | ||
Trial results: (No results available) |
EudraCT Number: 2013-000051-40 | Sponsor Protocol Number: LTS13632 | Start Date*: 2013-12-16 | |||||||||||
Sponsor Name:Genzyme Corporation | |||||||||||||
Full Title: A Long-Term Study to Assess the Ongoing Safety and Efficacy of Olipudase Alfa in Patients With Acid Sphingomyelinase Deficiency | |||||||||||||
Medical condition: Patients with acid sphingomyelinase deficiency (Niemann-Pick Type B disease) | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) IT (Completed) DE (Completed) BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-005834-19 | Sponsor Protocol Number: GBG44 | Start Date*: 2007-10-27 |
Sponsor Name:GBG Forschungs GmbH | ||
Full Title: A phase III trials program exploring the integration of Bevacizumab, Everolimus (RAD001), and Lapatinib into current neoadjuvant chemotherapy regimes for primary breast cancer | ||
Medical condition: breast cancer, primary systemic therapy | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
